CN106110336A - A kind of construction method of esophageal carcinoma chemoprophylaxis research mode - Google Patents
A kind of construction method of esophageal carcinoma chemoprophylaxis research mode Download PDFInfo
- Publication number
- CN106110336A CN106110336A CN201610660032.3A CN201610660032A CN106110336A CN 106110336 A CN106110336 A CN 106110336A CN 201610660032 A CN201610660032 A CN 201610660032A CN 106110336 A CN106110336 A CN 106110336A
- Authority
- CN
- China
- Prior art keywords
- esophageal
- cell
- chemoprophylaxis
- esophageal carcinoma
- induction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/008—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion lipoprotein vesicle, e.g. HDL or LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application belongs to treatment of cancer and prevention technique field, relates to the construction method of a kind of esophageal carcinoma chemoprophylaxis research mode.The method includes the steps such as the evaluation of the evaluation of dosing, the selection of laboratory animal, the chemical induction of the esophageal carcinoma, chemical agent action effect.The application mentality of designing is: in induced rat canceration course of esophageal, by affecting the incidence rate of precancerous lesion, multiformity, and being evaluated with esophageal canceration index of correlation developed by molecule situation by enzyme-linked immunosorbent assay for measuring pair, thus the chemoprevention efficacy of accurate evaluation related chemistry prevention medicament.As a example by NMBA induction esophageal canceration model, inventor has carried out concrete evaluation to the effect in esophageal carcinoma chemoprophylaxis of the different rhamnol, result shows, this evaluation methodology is the most objective and comprehensive, has established good basis for the application further in esophageal carcinoma chemoprophylaxis of the different rhamnol；Also the standardization for the prevention of other associated cancers and treatment provides reference and reference.
Description
Technical field
The application belongs to treatment of cancer and prevention technique field, is specifically related to a kind of esophageal carcinoma chemoprophylaxis research mode
The patent application of construction method.
Background technology
The esophageal carcinoma is one of modal malignant tumor in the world, in causing the modal tumor of cancer mortality, and position
Occupying the 6th, poor prognosis, five year survival rate is only 8 ~ 12%.Esophageal squamous cell carcinoma (esophageal squamous cell
Carcinoma, ESCC) and adenocarcinoma of esophagus (esophageal adenocarcinoma, EAC) be two main group of the esophageal carcinoma
Knit type.ESCC is the modal hypotype of developing country, but is mainly EAC in the U.S. and other western countries' esophageal carcinoma.
In recent years, although esophageal carcinoma early screening, early diagnosis technology have had progress, the chemotherapy and radiation of standard is applied the most clinically
Decades, but the survival rate of most of clinical middle and advanced stage patient is still not improved, and has pointed out and only emphasizes tumor early discovery
Ignoring tumor prevention with treatment, result produces little effect.
Certain cancers is preventable, and as far back as 20th century the mid-80, the World Health Organization (WHO) is the clearest and the most definite
Propose the viewpoint of 3 1/3, the cancer of i.e. 1/3 can be prevented, and the cancer patient of 1/3 can cure, and the patient of 1/3 is positive
Can improve the quality of living after treatment, extend life cycle.Now studies have found that esophageal canceration is a multistage Progressive symmetric erythrokeratodermia development
Process (normal-basal cell hyperplasia-atypical hyperplasia-cancer in situ-esophageal squamous cell carcinoma), and establish precancerous lesion
Concept.Esophageal precancerous lesion presents the unstable characteristic of clearly bi-directional development, i.e. these pathological changes can be developed to the direction of cancer,
The most reversible forward more slight pathological changes to, or maintain same state the most constant.This feature of precancerous lesion of cancer of esophagus is pointed out such as
Fruit gets involved intervention in early days, and precancerous lesion may be reversed or evolution is blocked, thus suppresses the generation of the esophageal carcinoma and send out
Exhibition.The gene and/or the precancerous lesion that are best understood from precancerous lesion of cancer of esophagus can be to the key molecules determining that precancerous lesion develops
Play a decisive role, accordingly, it would be desirable to exploitation is for the safe and effective targeted drug of these key genes, and then reverse, suppression,
Or stopping precancerous lesion progressing to cancer further.Therefore build can simulate the animal model of carcinogenesis of human esophageal carcinoma can
Think that esophageal carcinoma chemoprophylaxis provides a good thinking.
Esophageal carcinoma generation development is the result of environmental factors and interaction of genes.By to Henan area Esophageal Cancer
The epidemiological investigation of district crowd, finds Methyl jasmonate (N-nitrosomethylbenzylamine, NMBA)
With the esophageal carcinoma, there is close positive correlation.The rat esophagus squamous cell carcinoma model of NMBA induction at present, widely
For assessing the pathophysiological processes that the esophageal carcinoma occurs, to confirm chemoprophylactic drug application prospect in human studies.
Rat is developed into squamous cell carcinoma from normal epithelium of esophagus and experienced by hypertrophy, leukoplakia, atypical hyperplasia, papilloma,
This strain responses is very much like with human pathological's process, can fully simulate the process of people's epithelium of esophagus canceration, uses this to move
Object model can inquire into the molecular mechanism of canceration course of esophageal further, thus for finding molecular target, and be screening further
Intervene or delay the esophageal carcinoma to occur the cancer chemoprevention medicine of development to provide a platform.
The esophageal carcinoma chemoprevention of cancer research in, in addition to vitamin and various trace elements, multiple compounds also by with
Attempt carrying out the chemoprophylaxis research of the esophageal carcinoma, such as tea polyphenols, freeze-dried strawberry, gallic acid, antioxidation class and nonsteroidal
Anti-inflammatory drugs etc., these compounds prevent generation and the development of the esophageal carcinoma by different targeted moleculars, but its mechanism of action is also
Need to study deeper into ground.But preventing target spot according to the predetermined esophageal carcinoma, screening safety is good, the change of excellent in efficiency, low toxicity
Compound is the basic engineering target carrying out esophageal carcinoma prevention.But in general, owing to lacking the chemoprophylaxis of a kind of more standard
Study model and the construction method of chemoprophylaxis model, thus when evaluating based on distinct methods, the action effect of identical medicament can
Certain difference can be there is, to a certain degree have impact on the chemoprophylactic development of the esophageal carcinoma.
Summary of the invention
The application purpose is to provide the construction method of a kind of esophageal carcinoma chemoprophylaxis research mode, thus is the esophageal carcinoma
The standardization of chemoprophylactic zootype and the accurate evaluation of related agents action effect lay the foundation.
Details are as follows for the technical scheme that the application is taked.
The construction method of a kind of esophageal carcinoma chemoprophylaxis research mode, the method is mainly used in evaluating particular agent at esophagus
Action effect in cancer chemoprevention, specifically includes following steps:
(1) first the inhibitory action of cytotoxicity, cell proliferation and the conversion of chemoprophylaxis medicament is carried out preliminary assessment, with
Determine the optimum dose scope of chemical agent；Described cell is specifically for example with SHEE cell；
(2) secondly, for obtaining good esophageal canceration model, suitable laboratory animal is selected, concrete as selected F344 rat, so
After adapt to after environment in laboratory animal, be randomly divided into some groups, at least a part of which includes blank group (i.e., normally feeding), food
Pipe cancer induction group (as used the esophageal canceration group of NMBA induction) and experimental group (i.e. in esophageal carcinoma Induction Process, are simultaneously introduced
Chemoprophylaxis medicament, is evaluated with the chemoprevention efficacy to medicament)；
(3) induce according to the chemical induction process of the esophageal carcinoma, as a example by the esophageal canceration model of NMBA induction, for F344
Rat, according to the amount subcutaneous injection of NMBA 0.25 ~ 0.5 mg/kg, 3 times/all, continuous 5 weeks (or 1 time/all, continuous 15
Week)；Experimental group, while carrying out esophageal carcinoma induction, uses chemoprophylaxis medicament the most in good time, feeds as carried the last week
Chemoprophylaxis medicament, then carries out the induction of esophageal canceration according still further to normal induction program, and the induction end time induces with NMBA
Group；
During Induction experiments, laboratory animal ad lib, drinking-water；
(4) specifically evaluating the action effect of chemoprophylaxis medicament, evaluation criterion includes:
The morphological features such as each the group diet of laboratory animal, drinking-water, body weight；
Evaluation in terms of the tissue morphology change of esophageal cancer cell, as Esophageal Mucosa epithelium is divided into normally, hypertrophy, mucosa white
Speckle, atypical hyperplasia 4 type, then add up the situation of change of several organization types；The concrete boundary of 4 kinds of change types
Calibration standard is:
Normally, normal esophageal squamous epithelial cancer, unchanged；
Hypertrophy, Accretive Type pathological changes is divided into basal cell hyperplasia, epithelial cell (spine cell) hypertrophy；
Mucous membrane white spot, basal cell and spine cell significantly increase, and the basal cell of hypertrophy forms more than 3-6 layer, can account for holostrome
1/2；
Atypical hyperplasia, basal layer cell active proliferation, level is disorderly and more, and basad portion highlights, and can exceed epithelium holostrome
2/3；Cell increases, and size and form are inconsistent, arrange the most whole；
Evaluation molecules level in terms of relevant to esophageal cancer cell pathological changes, the change such as COX-2 index expression is carried out
Evaluate.
The general design idea of the application is: utilizes and builds the esophageal epithelial cell transformation model of carcinogenic promoting agent induction and causing
Cancer agent induced rat esophageal canceration model, by calculating the incidence rate of precancerous lesion, multiformity, and passes through Enzyme-linked Immunosorbent Assay
Assay method pair is evaluated with esophageal canceration index of correlation developed by molecule situation, thus accurate evaluation related chemistry prevention medicament
Chemoprevention efficacy.
According to the method described above, the chemoprophylaxis research of the esophageal canceration animal model of a kind of NMBA induction is inventor provided
Pattern, and the effect in esophageal carcinoma chemoprophylaxis of the different rhamnol has been carried out concrete evaluation, result shows, this evaluation methodology
The most objective and comprehensive, establish good basis for the application further in esophageal carcinoma chemoprophylaxis of the different rhamnol；The most originally
Application also provides reference and reference for the prevention of other associated cancers and the standardization treated.
Accompanying drawing explanation
What Fig. 1 was different rhamnol on SHEE cell proliferation and conversion affects result, and wherein A is for detect by CCK8 test kit
Different rhamnol is to people's immortalized esophageal Cytotoxic experimental result of cell SHEE, the survival rate of 10 μMs of different rhamnol cells in figure
About 80%；B is that SHEE cell growth inhibition result, its result are shown by different rhamnol, when 0 ~ 10 μM, and different Fructus rhamni (Rhamnus davurica Pall.)
Alcohol has time and dose dependent to the inhibitory action of SHEE cell；C is the different rhamnol shadow to SHEE cell transformation capacity
Ringing result, its result shows, along with the rising of different rhamnol concentration, cell transformation capacity and clone's quantity decline, and different rhamnol
EGF can be suppressed to induce SHEE transformation；
During Fig. 2 is for experiment, rat general physiology statistical indicator situation, wherein A is each group of rat body weight situation, compares for each group
No significant difference；B is that each group of rat chow takes in situation, compares no significant difference for each group, and C is each group of rat
Drinking-water situation, compares no significant difference for each group；
Fig. 3 is rat esophagus mucosa staining pathological grading canonical reference figure, and wherein A is NMBA group rat esophagus mid-stream sample shape
State observes figure；In B, a is normal esophageal mucosa, and b is Esophageal Mucosa proliferative lesion, and c is that Esophageal Mucosa white macula sexually transmitted disease (STD) becomes, and d is
Esophageal Mucosa atypical hyperplasia (× 400)；
Fig. 4 is 15 weeks, 25 weeks, 35 weeks time, rat esophagus mucosa infection statistical result；
Fig. 5 is 15 weeks, 25 weeks, 35 weeks time, rat blood serum COX2 statistical result；
Rat blood serum COX2 assay result is respectively organized when Fig. 6 is 35 weeks.
Detailed description of the invention
Below in conjunction with embodiment, technical scheme is described in detail, before introducing embodiment, the most right
In the present invention, part Experiment material used and animal model build and are briefly discussed below.
Cell strain: SHEE cell strain (Shantou human embryonic esophageal epithelial cell
Line), people's embryo esophageal epithelial cell Shantou strain, also referred to as Immortalized Esophageal Epithelial Cells strain, by Medical College of Shantou University oncosis
Reason research department professor Li Enmin give, and cell strain uses 10% FBS/DMEM culture medium, 37 DEG C of constant temperature, 5% CO in incubator2Bar
Under part cultivate, standby.
The structure of the rat esophagus canceration model of NMBA induction:
In animal model building process, rat used is: male, the F344 rat (purchased from Beijing dimension tonneau China) of 4 ~ 5 week old；Mould
In type building process, rat is raised by 5/cage standard conditions, constant temperature (22～25 DEG C), constant humidity (40～60%), every 12 hours
Light dark cycle once, freely eats for animal through autoclaved cleaning grade animal feed and water；Within two weeks, change a mouse cage,
And regular clean animal room；
The rat esophagus canceration model building process of NMBA induction is:
By the amount of subcutaneous injection NMBA 0.5mg/kg, (it is revised as also dependent on needs: for 3 times/all, continuous 5 weeks for 1 time/week, continuously
15 weeks) mode builds rat esophagus carcinoma animal model, and puts to death a collection of rat 15 weeks, 25 weeks and 35 weeks respectively, thus point
Rat esophagus precancerous lesion process is classified and quantifies (refinement) by the stage, is beneficial to find the base that each stage changes
Cause, by analyzing the molecular mechanism of precancerous lesion, thus selects chemoprophylaxis target spot to provide theoretical foundation for different phase；
In the most following embodiment, when carrying out compound prevention esophageal canceration experiment, give NMBA subcutaneous injection the last week to
Give medicine gavage, carry out the chemoprophylaxis of medicine.
Embodiment
With the rat esophagus canceration model of NMBA induction with to the effect in the chemoprophylaxis of the esophageal carcinoma of the different rhamnol
As a example by, the construction method of esophageal carcinoma chemoprophylaxis zootype provided herein is briefly discussed below.
The construction method of esophageal carcinoma chemoprophylaxis zootype provided herein, concrete construction step is as described below.
(1) first, the inhibitory action of cytotoxicity, cell proliferation and the conversion of chemoprophylaxis medicament is tentatively commented
Valency, to determine the optimum dose scope of chemical agent；
The present embodiment is mainly as a example by different rhamnol Evaluation of Utility in esophageal carcinoma chemoprophylaxis, thus first to different Mus
Lee's alcohol is preliminary assessment, phase to the inhibitory action of the cytotoxicity of SHEE cell, the inhibitory action of cell proliferation and cell transformation
Pass experiment is briefly discussed below.
Cytotoxicity experiment
Experimentation is: SHEE cell is with 1 × 104Individual/every hole be inoculated in 96 orifice plates carry out cultivating (10% FBS/DMEM, 37 DEG C,
5% CO2), after 12 hours, change fresh culture and add variable concentrations different rhamnol (0 μM, 1 μM, 2.5 μMs, 5 μMs,
10 μMs, 20 μMs), after cultivating 24 and 48 hours respectively, every hole adds 10 μ L CCK-8(cell counting kit-8, Japan
Colleague), continue to cultivate 2 hours, finally in microplate reader, 450nm carries out absorbance detection.
Experimental result is as shown in Figure 1A.It can be seen that pass through the detection of CCK8 test kit from Figure 1A, it appeared that 0 ~ 10
μM different rhamnol the least to the toxicity of cell, but the different rhamnol of 20 μMs shows certain cytotoxicity.Thus
Subsequent experimental selects 10 μMs as experiment maximum dose level.
Cell proliferation experiment
Experimentation is: SHEE cell is with 5 × 103Individual/every hole be inoculated in 96 orifice plates carry out cultivating (10% FBS/DMEM, 37 DEG C,
5% CO2), after 12 hours, change fresh culture and add variable concentrations different rhamnol (0 μM, 1 μM, 2.5 μMs, 5 μMs, 10
μM), respectively after cultivating 0,24,48,72 and 96 hours, every hole adds the CCK8 of 10 μ L, continues to cultivate 2 hours, finally at enzyme
Absorbance detection is carried out under 450nm wavelength condition on mark instrument.
Experimental result is as shown in Figure 1B.
It can be seen that the different rhamnol effect SHEE cell of 1 μM, 2.5 μMs concentration 24,48,72 and 96 hours from Figure 1B
After, SHEE cell is not had inhibitory action, the different rhamnol of 5 μMs, 10 μMs concentration is inhibited to SHEE cell, and in
Between Xian Shi and dose dependent.
Anchorage Independent growth experiment
Experimentation is: on 6 orifice plates, every hole spreads into 3 ml BME culture medium (containing 10% FBS and 0.5% agar), to be solidified after
Spread and have 8 × 10 into suspendible3The upper strata glue (1 mL BME culture medium, containing 10% FBS and 0.33% agar) of individual SHEE cell,
Incubator (37 DEG C, 5% CO2) cultivate after 7 days, treat Clone formation, utilize microscope to carry out colony count.
Experimental result is as shown in Figure 1 C.
From Fig. 1 C it can be seen that with EGF(epithelical cell growth factor) group compares, DMSO(dimethyl sulfoxide) solvent pair
SHEE cell according to group does not has clonality；After SHEE cell is induced by EGF, cell forms clone, but adds different Mus
Lee's alcohol can suppress the SHEE cell clonal formation that EGF induces, and along with the rising of different rhamnol concentration, clone's quantity is gradually
Declining, illustrate in the case of low toxic concentration, different rhamnol can suppress the SHEE cell clonal formation energy that EGF induces
Power.
The to sum up conclusion such as cytotoxicity, cell proliferation, grappling experiment, it can be assumed that, the different rhamnol of less than 10 μMs concentration
To the toxicity of SHEE cell at tolerance interval, and in this concentration range, different rhamnol has increasing to SHEE cell
Grow inhibitory action；And the SHEE transformation induced EGF due to different rhamnol is inhibited, thus can tentatively recognize
Fixed, different rhamnol has the suppression normal cell effect to tumour cell transformation under low consistency conditions, in other words, in safety
On different rhamnol drug level scope (when less than 10 μMs), can effectively suppress the propagation of SHEE cell and pernicious turn
Change.
(2) selecting suitable laboratory animal, the application, as a example by the esophageal precancerous lesion that NMBA induces, have employed F344 big
Mus, after rat adapts to experimental situation, is randomly divided into some groups；
In the present embodiment, based on different rhamnol usage variance and adjuvant influence factor consider, be provided with 5 groups altogether, specifically
For:
First group: solvent control group (rat quantity n=20), conventional raising, subcutaneous injection sterilized water, three-times-weekly, totally five weeks；
Press the carboxymethyl cellulose of the dosage gavage 0.5% of rat body weight 1mL/100g, once a day, totally 35 weeks simultaneously；
Second group: NMBA model group (rat quantity n=33), conventional raising, subcutaneous injection NMBA, three-times-weekly, totally five weeks；
3rd group: zengshengping tablet group (rat quantity n=8), on the basis of NMBA injects, simultaneously with zengshengping tablet to rat oral gavage (4g/
Kg), once a day, totally 35 weeks；
4th group: different rhamnol low dose group (rat quantity n=10), on the basis of NMBA injects, by 10mg/kg dosage by different
Rhamnol is suspended in 0.5% carboxymethyl cellulose and carries out gavage, once a day, carries out altogether 35 weeks；
5th group: different rhamnol high dose group (rat quantity n=10), on the basis of NMBA injects, by 50mg/kg dosage by different
Rhamnol is suspended in 0.5% carboxymethyl cellulose and carries out gavage, once a day, carries out altogether 35 weeks.
It is to be understood that during experimental design, as required experiment group can suitably be adjusted, but typically at least should include
Blank group, esophageal carcinoma induction group and three groups of experimental group, to specified chemical medicament in esophageal carcinoma chemoprophylaxis
Effect carries out preliminary assessment.
(3) induce according to the chemical induction process of the esophageal carcinoma, according to above-mentioned NMBA abductive approach, in step (2)
The laboratory animal of different groups carries out the induction of esophageal canceration；During each group all carries out 35 weeks duration Induction experiments, experiment
Animal ad lib, drinking-water.
(4) specifically evaluating the action effect of chemoprophylaxis medicament, evaluation criterion includes 3 levels altogether, i.e. form
Learn level, cytology's level and molecular structure level, be described in detail as follows.
First, the morphological features such as the diet of each group of laboratory animal, drinking-water, body weight are carried out statistics and analysis.Experiment knot
Fruit is as shown in Figure 2.
It can be seen that respectively group rat does not has notable difference in terms of body weight and food intake, amount of drinking water.This result
Showing, chemoprophylaxis medicament does not affect for the normal growth of laboratory animal, has preferable application foundation.
Secondly, the tissue morphology change aspect of esophageal epithelial cell is evaluated.In the present embodiment, by Esophageal Mucosa
Skin is divided into normally, hypertrophy, mucous membrane white spot, atypical hyperplasia 4 type, then to the change of several organization types in different groups
Situation is added up；
The concrete defining standard of 4 kinds of change types is:
Normally, normal esophageal squamous epithelial cancer, unchanged；
Hypertrophy, Accretive Type pathological changes is divided into basal cell hyperplasia, epithelial cell (spine cell) hypertrophy；
Mucous membrane white spot, basal cell and spine cell significantly increase, and the basal cell of hypertrophy forms more than 3-6 layer, can account for holostrome
1/2；
Atypical hyperplasia, basal layer cell active proliferation, level is disorderly and more, and basad portion highlights, and can exceed epithelium holostrome
2/3；Cell increases, and size and form are inconsistent, arrange the most whole；
Typical 4 kinds of tissue change types in mucous membrane of esophagus sample are as it is shown on figure 3, in this, as comparison and reference, to different groups
In not, the tissue change situation of 4 types is added up, F344 rat esophagus cancerous issue situation of change knot in concrete each group
(in table, data are mean ± standard deviation) the most as shown in the table:
Different rhamnol is on F344 rat esophagus canceration degree and the impact of quantity:
Note:aRepresent compared with NMBA group, difference statistically significant (P< 0.05),bRepresenting compared with NMBA group, difference has system
Meter meaning (P< 0.01),cRepresent compared with NMBA group, difference statistically significant (P< 0.001).
Further, respectively to 15 weeks, 25 weeks, 35 weeks time NMBA group rat esophagus mucosa infection situation add up, knot
The most as shown in Figure 4,
Figure 4, it is seen that compared with matched group, NMBA group 15 weeks, 25 weeks, 35 weeks time hypertrophy, leukoplakia and non-allusion quotation
Type preneoplastic lesions showed increased, difference statistically significant (P < 0.05).Specifically:
Hypertrophic change, 35 weeks obvious hypertrophy of mucous membrane of esophagus, pathological changes increases, with 15 weeks, compared with 25 weeks variant, difference has statistics
Learn meaning (P < 0.001)；
Leukoplakia, within 35 weeks, rat esophagus pathological changes is compared with 15 weeks, and leukoplakia increases, difference statistically significant (P <
0.05)；
Atypical hyperplasia, 35 weeks compared with 15 weeks lesion degree serious, difference statistically significant (P < 0.05).
Evaluation result in terms of summary tectology is it can be seen that by the induction of NMBA, can successfully build mark
The esophageal canceration model animal of standardization, and by the quantitative criterion to esophageal tissue's canceration degree, it can be seen that different rhamnol
In stoping canceration course of esophageal, there is preferable intervention effect, can be that the chemoprophylaxis of the esophageal carcinoma provides preferably reference
Effect.
Finally, by the evaluation in terms of the molecules level relevant to esophageal cancer cell pathological changes, as change of serum C OX2 is changed
Situation is evaluated, thus understands the mechanism of action of chemoprophylaxis medicament in depth, simultaneously the most also for related chemistry medicament more preferably, more have
The prevention esophageal canceration of effect lays the foundation.
Respectively to 15 weeks, 25 weeks, 35 weeks time NMBA group rat blood serum COX2 content be measured, result is as shown in Figure 5.From
It can be seen that compared with matched group, NMBA group is rat blood serum COX2 content showed increased when 35 weeks, and difference has statistics in figure
Meaning (P < 0.05).35 weeks NMBA groups with 15 weeks, compared with 25 weeks NMBA groups, rat blood serum COX2 content showed increased, difference has
Statistical significance (P < 0.05)
And being measured respectively organizing rat blood serum COX2 content during 35w, result is as shown in Figure 6.It can be seen that with
NMBA group is compared, and zengshengping tablet group and the different rhamnol high dose rat blood serum COX2 content when 35 weeks significantly reduces, and difference has system
Meaning (P < 0.05) learned by meter.
In sum, the application is by combining the building process of canceration course of esophageal animal model, it is provided that a kind of esophagus
The construction method of cancer chemoprevention zootype, and as a example by F344 rat, construct one the most standardized NMBA induction
Different rhamnol chemoprophylaxis animal model, by the foundation of different levels appraisement system, evaluation that can be the most comprehensive and accurate
Different rhamnol elemental abundances in esophageal canceration, is also other medicaments elemental abundances in associated cancer simultaneously
Provide reference and reference.
Claims (5)
1. the construction method of an esophageal carcinoma chemoprophylaxis research mode, it is characterised in that the method specifically includes following steps:
(1) first, the inhibitory action of cytotoxicity, cell proliferation and the conversion of chemoprophylaxis medicament is evaluated, with really
Determine the optimum dose scope of chemical agent；
(2) secondly, selecting suitable laboratory animal, after laboratory animal answers environment, be randomly divided into some groups, at least a part of which includes
Blank group, esophageal carcinoma induction group and experimental group；
(3) inducing according to the chemical induction process of the esophageal carcinoma, experimental group is while carrying out esophageal carcinoma induction, as required
Use chemoprophylaxis medicament；During Induction experiments, laboratory animal ad lib, drinking-water；
(4) action effect of chemoprophylaxis medicament is specifically evaluated, evaluation criterion bag:
Morphological feature in terms of each the group diet of laboratory animal, drinking-water, body weight；
Evaluation in terms of the tissue morphology change of esophageal epithelial cell Carcinogenesis；
Evaluation molecules level in terms of relevant to esophageal cancer cell pathological changes.
2. the construction method of esophageal carcinoma chemoprophylaxis research mode as claimed in claim 1, it is characterised in that institute in step (1)
State cell and use the esophageal epithelial cell of immortalization.
3. the construction method of esophageal carcinoma chemoprophylaxis research mode as claimed in claim 1, it is characterised in that institute in step (2)
Stating laboratory animal is F344 rat.
4. the construction method of esophageal carcinoma chemoprophylaxis research mode as claimed in claim 1, it is characterised in that institute in step (3)
State the chemical induction of the esophageal carcinoma and use NMBA induction, by the amount of 0.25 ~ 0.5 mg/kg, subcutaneous injection, 3 times/all, continuous 5 weeks,
Or 1 time/all, continuous 15 weeks.
5. the construction method of esophageal carcinoma chemoprophylaxis research mode as claimed in claim 1, it is characterised in that institute in step (4)
Stating the evaluation criterion in terms of the tissue morphology change of esophageal cancer cell is, Esophageal Mucosa epithelium is divided into normally, hypertrophy, mucosa white
Speckle, atypical hyperplasia 4 type, concrete defining standard is:
Normally, normal esophageal squamous epithelial cancer, unchanged；
Hypertrophy, Accretive Type pathological changes is divided into basal cell hyperplasia, epithelial cell (spine cell) hypertrophy；
Mucous membrane white spot, basal cell and spine cell significantly increase, and the basal cell of hypertrophy forms more than 3-6 layer, can account for holostrome
1/2；
Atypical hyperplasia, basal layer cell active proliferation, level is disorderly and more, and basad portion highlights, and can exceed epithelium holostrome
2/3；Cell increases, and size and form are inconsistent, arrange the most whole.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610660032.3A CN106110336A (en) | 2016-08-12 | 2016-08-12 | A kind of construction method of esophageal carcinoma chemoprophylaxis research mode |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610660032.3A CN106110336A (en) | 2016-08-12 | 2016-08-12 | A kind of construction method of esophageal carcinoma chemoprophylaxis research mode |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106110336A true CN106110336A (en) | 2016-11-16 |
Family
ID=57259198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610660032.3A Pending CN106110336A (en) | 2016-08-12 | 2016-08-12 | A kind of construction method of esophageal carcinoma chemoprophylaxis research mode |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106110336A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108715860A (en) * | 2018-04-20 | 2018-10-30 | 郑州大学 | A kind of construction method of epithelium of esophagus tissue p53 specific knockdowns mouse esophageal precancerous lesion model |
| CN112674028A (en) * | 2020-12-30 | 2021-04-20 | 汉姆德(宁波)智能医疗科技有限公司 | Method for establishing cancer model of animal induced by cancer inducer |
| CN114854669A (en) * | 2022-05-26 | 2022-08-05 | 东南大学 | Method for constructing esophageal epithelial cell precancerous lesion cell model |
-
2016
- 2016-08-12 CN CN201610660032.3A patent/CN106110336A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 杨超 等: ""食道癌细胞在异鼠李素处理中的应激作用研究"", 《四川大学学报》 * |
| 杨辉 等，: ""维生素E和硒对N-甲基节基亚硝胺诱发大鼠食管癌的化学预防作用"", 《食品饲料安全与风险评估学术会议论文集》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108715860A (en) * | 2018-04-20 | 2018-10-30 | 郑州大学 | A kind of construction method of epithelium of esophagus tissue p53 specific knockdowns mouse esophageal precancerous lesion model |
| CN112674028A (en) * | 2020-12-30 | 2021-04-20 | 汉姆德(宁波)智能医疗科技有限公司 | Method for establishing cancer model of animal induced by cancer inducer |
| CN112674028B (en) * | 2020-12-30 | 2022-06-28 | 汉姆德(宁波)智能医疗科技有限公司 | Method for establishing cancer model of animal induced by cancer inducer |
| CN114854669A (en) * | 2022-05-26 | 2022-08-05 | 东南大学 | Method for constructing esophageal epithelial cell precancerous lesion cell model |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diao et al. | Astilbin protects diabetic rat heart against ischemia–reperfusion injury via blockade of HMGB1-dependent NF-κB signaling pathway | |
| JP2009515977A (en) | Scutellaria barbata extract for the treatment of cancer | |
| RU2554497C2 (en) | Composition for injections containing hydroxychloroquine for local application in treating cancer | |
| Gao et al. | Huganpian, a traditional Chinese medicine, inhibits liver cancer growth in vitro and in vivo by inducing autophagy and cell cycle arrest | |
| CN106110336A (en) | A kind of construction method of esophageal carcinoma chemoprophylaxis research mode | |
| CN102218140B (en) | Tumor resistance effect of medicine combination of salvianolic acid B and coxib medicaments | |
| CN105343897B (en) | Rhesus macaque liver cancer model, rhesus macaque hepatoma cell strain and application thereof | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN100553629C (en) | The application of paeonol in preparation anti esophageal cancer medicine | |
| CN113018284A (en) | Method for inducing lung adenocarcinoma NCI-H1299 cell scorch by sodium new houttuyfonate | |
| CN106265629A (en) | The application in esophageal carcinoma chemoprophylaxis of the different rhamnol | |
| CN102440987B (en) | Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof | |
| CN113440519A (en) | Application of mycophenolic acid and derivatives thereof in preparation of drugs for targeted therapy of cancers | |
| CN103494822B (en) | A kind of compound anti-cancer medicine combining Statins pravastatin and thiazide antihypertensive drug | |
| Martins-Perles et al. | Quercetin supplementation prevents changes in the serotonin and caspase-3 immunoreactive cells of the jejunum of diabetic rats | |
| CN104922268A (en) | Method for extracting active substances from natural plants | |
| CN100473416C (en) | Preparation of Chinese traditional medicine for treating gastric disease, and preparation method thereof | |
| CN116687913B (en) | Application of mycophenolic acid in preparation of medicine for treating esophageal cancer | |
| CN105853402B (en) | A kind of purposes of terpene complex ester | |
| CN104971059A (en) | Application of niclosamide or pharmaceutically acceptable salt thereof in pharmacy | |
| CN101856393B (en) | Application of compound Yiganling composition in aspect of auxiliary treatment of chemotherapy of tumors | |
| CN113209063B (en) | Application of damnacanthal in preparation of medicine for treating ovarian cancer | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions | |
| CN105878253A (en) | Medical application of corosolic acid | |
| CN102949399B (en) | Tanshinone ⅡA suppresses the application in keratinocyte proliferation disease medicine in preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |
|
| RJ01 | Rejection of invention patent application after publication |